(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.95%) $83.05
(-1.16%) $1.619
(-0.28%) $2 340.70
(-0.27%) $27.46
(0.52%) $926.90
(-0.11%) $0.934
(-0.09%) $11.02
(-0.17%) $0.799
(0.00%) $92.17
-0.09% INR 1 079.35
Live Chart Being Loaded With Signals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally...
Stats | |
---|---|
Tagesvolumen | 475 439 |
Durchschnittsvolumen | 1.23M |
Marktkapitalisierung | 304.58B |
EPS | INR-12.45 ( 2024-02-15 ) |
Nächstes Ertragsdatum | ( INR7.93 ) 2024-05-15 |
Last Dividend | INR2.50 ( 2023-09-18 ) |
Next Dividend | INR0 ( N/A ) |
P/E | -39.84 |
ATR14 | INR1.149 (0.11%) |
Volumen Korrelation
Glenmark Pharmaceuticals Korrelation
10 Am meisten positiv korreliert | |
---|---|
AUROPHARMA.NS | 0.938 |
ADORWELD.NS | 0.93 |
ANURAS.NS | 0.923 |
IZMO.NS | 0.914 |
GISOLUTION.NS | 0.907 |
ANMOL.NS | 0.905 |
CAREERP.NS | 0.889 |
KSB.NS | 0.884 |
SETF10GILT.NS | 0.879 |
GTNTEX.NS | 0.876 |
10 Am meisten negativ korreliert | |
---|---|
KOHINOOR.NS | -0.876 |
SEYAIND.NS | -0.867 |
DEEPINDS.NS | -0.855 |
MERCATOR.NS | -0.849 |
STARTECK.NS | -0.835 |
ALLCARGO.NS | -0.808 |
ORTINLAB.NS | -0.807 |
KBCGLOBAL.NS | -0.803 |
SWANENERGY.NS | -0.803 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Glenmark Pharmaceuticals Korrelation - Währung/Rohstoff
Glenmark Pharmaceuticals Finanzdaten
Annual | 2022 |
Umsatz: | INR127.25B |
Bruttogewinn: | INR81.88B (64.35 %) |
EPS: | INR10.53 |
FY | 2022 |
Umsatz: | INR127.25B |
Bruttogewinn: | INR81.88B (64.35 %) |
EPS: | INR10.53 |
FY | 2022 |
Umsatz: | INR121.74B |
Bruttogewinn: | INR77.14B (63.37 %) |
EPS: | INR33.37 |
FY | 2021 |
Umsatz: | INR108.06B |
Bruttogewinn: | INR70.62B (65.35 %) |
EPS: | INR34.38 |
Financial Reports:
No articles found.
Glenmark Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR2.50 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR2.50 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.600 | 2002-09-12 |
Last Dividend | INR2.50 | 2023-09-18 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 22 | -- |
Total Paid Out | INR30.90 | -- |
Avg. Dividend % Per Year | 0.37% | -- |
Score | 1.29 | -- |
Div. Sustainability Score | 0.0208 | |
Div.Growth Potential Score | 2.81 | |
Div. Directional Score | 1.416 | -- |
Year | Amount | Yield |
---|---|---|
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR2.00 | 0.38% |
2019 | INR2.00 | 0.29% |
2020 | INR2.50 | 0.72% |
2021 | INR2.50 | 0.50% |
2022 | INR2.50 | 0.48% |
2023 | INR2.50 | 0.59% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TINPLATE.NS | Dividend Junior | 2023-08-11 | Annually | 19 | 0.72% | |
PDMJEPAPER.NS | Dividend Junior | 2023-08-03 | Annually | 9 | 0.65% | |
J&KBANK.NS | Dividend Junior | 2023-08-17 | Sporadic | 22 | 0.47% | |
DATAMATICS.NS | Dividend Junior | 2023-09-22 | Annually | 21 | 0.49% | |
SHYAMMETL.NS | Dividend Junior | 2023-06-05 | Semi-Annually | 4 | 0.70% | |
MAXHEALTH.NS | Dividend Junior | 2023-09-08 | Insufficient data to determine frequency | 2 | 0.07% | |
GSPL.NS | Dividend Junior | 2023-09-01 | Annually | 19 | 0.81% | |
BANKINDIA.NS | Dividend Junior | 2023-06-20 | Sporadic | 23 | 1.34% | |
PRAJIND.NS | Dividend Junior | 2023-07-19 | Annually | 22 | 0.83% | |
KABRAEXTRU.NS | Dividend Junior | 2023-07-13 | Annually | 23 | 0.83% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0581 | 1.500 | -1.161 | -1.742 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | -0.0742 | 1.500 | -1.935 | -2.90 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 1.901 | 1.000 | -0.407 | -0.407 | [3 - 30] |
operatingCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.621 | 1.000 | 2.99 | 2.99 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0740 | 1.000 | -0.520 | -0.520 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 0.0208 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -42.79 | 1.000 | -4.42 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0742 | 2.50 | -1.244 | -2.90 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.232 | 1.500 | 4.21 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.625 | 1.500 | 9.17 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0729 | 1.000 | -0.678 | 0 | [0.1 - 0.5] |
Total Score | 2.81 |
Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.